Visit
Spinal muscular atrophy (SMA) is a severe genetic disease associated with mutations in the SMN1 gene (SMA5q). The pathological characteristics…
The Food and Drug Administration (FDA) approved ublituximab for the treatment of relapsing forms of multiple sclerosis (MS), making it…
In this feature, we spotlight hot topics in MS discussed at ECTRIMS, from the inclusion of optic nerve lesions in…
The MR CLEAN-LATE prospective, randomized study of over 500 patients with acute ischemic stroke showed that endovascular thrombectomy (EVT) provides…
On September 29, 2022, the Food and Drug Administration (FDA) approved AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS),…
A wealth of research continues to investigate anticoagulation-associated intracranial hemorrhage and the optimal strategies for prevention and management…
The European Stroke Organisation (ESO) has published new guidelines for prehospital management of suspected stroke patients, and recommendations, in collaboration…
New treatment strategies are gaining attention in epilepsy, where current therapeutic options are ineffective for many. Learn more about the…
Biomarker research was a major talking point at ECTRIMS 2021. Discover the latest developments discussed at the meeting, from moving…
An overview covering some of the exciting research and scientific advances presented at the 7th European Stroke Organisation Conference (ESOC…
The results of the Phase III AMBAR trial were presented at the 2021 EAN meeting. Read on to learn more…
